The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.

RBC Capital analyst Craig Wong-Pan maintained a Hold rating on Resmed (RMD – Research Report) on January 29 and set a price target of $238.00.

Reports Q2 revenue $1.28B, consensus $1.27B. “Our second quarter fiscal year 2025 top-line growth, margin expansion, and double-digit EPS ...

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...